This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Drug discovery is a complex and vital field that continually seeks to identify new therapeutic targets and develop effective treatments. In recent years, a novel approach known as condensate biology has emerged, revolutionising the way researchers think about drug discovery and development.
The bulk of my nearly three decades of experience up to that point was with drugging protein targets using a variety of modalities, but principally smallmolecules. It’s all well and good to say, “we should drug RNA,” but which RNA? Prior to 2015, I had a casual relationship, at best, with targeting RNA.
Shortly after finishing my studies, I landed my first job in industry working on cellbiology research for several disease indications. These are two essential signalling nodes in genetically and clinically validated pathways driving inflammation in autoimmune diseases that are undrugged or inadequately drugged with other technologies.
Notably, it has been shown that LPA is a cell motility factor and inhibition of ATX results in a decrease of cellular invasion through a reduction of LPA concentration in the surrounding fluids in vitro. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Med Chem.
They then developed a new therapeutic approach with a potent small-molecule inhibitor of this enzyme. Certain subtypes of blood cancers such as acute leukemias rely on multiple mechanisms for sustaining growth of aggressive cancer cells. Their findings are published online in Nature CellBiology.
The goals for Sunesis had such an impact on my current research, as did the early days of thinking about what we call fragment-based drug discovery. Thus, you don’t have to find a molecule that fills that whole interface, which is much larger than a drug-like molecule. So this work can have a valuable impact.
Webinar | Ai At The Frontier: Empowering Early Career Professionals In Drug Discovery WEBINAR – ARE YOU CURIOUS ABOUT THE CUTTING-EDGE INTERSECTION OF ARTIFICIAL INTELLIGENCE AND DRUG DISCOVERY? Are you curious about the cutting-edge intersection of Artificial Intelligence and Drug Discovery?
When bound to GRP78, ID2 loses its inhibitory function, leading to increased invasiveness of cancer cells. Implications for cancer therapeutics and beyond These findings have wide-ranging implications for cancer treatment and cellbiology research.
Not only does this discovery raise hope for better treatments for many parasitic and bacterial diseases, it highlights the value of screening peptides in the search for ways to treat conditions that do not respond well—or have stopped responding—to more traditional chemical drug compounds. All of their hard work came up empty.
Where do you see the future of mRNA biology and AI converging, and how does Anima Biotech plan to lead this convergence? mRNA biology has become widely recognised as a new “drug mine” RNAi drugs are in the market and mRNA vaccines, initially developed for Covid-19, are already in trials for cancer.
An open-source FACS automation system for high-throughput cellbiology. Cell Systems. Read Small-molecule aptamer for regulating RNA functions in mammalian cells and animals. Read The FDA is reviewing a “controversial cell therapy for ALS,” developed by BrainStorm Cell Therapeutics.
Read Stem cells were induced to form insulin-secreting pancreas cells and then transplanted into diabetic mice, where they successfully restored glucose levels. Nature CellBiology. Read Microbes in the wild ‘talk’ to their neighbors by emitting, and sensing, small chemicals. Cell Systems.
Read Stem cells were induced to form insulin-secreting pancreas cells and then transplanted into diabetic mice, where they successfully restored glucose levels. Nature CellBiology. Read Microbes in the wild ‘talk’ to their neighbors by emitting, and sensing, small chemicals. Cell Systems.
What are macrocycles and why are they interesting for drug discovery? Traditionally, drug discovery has focused on small-molecule therapeutics, typically with a molecular weight of less than 500 Daltons. 2 Typically, small-moleculedrugs target active sites buried inside proteins.
Nature CellBiology. Read *Open-endedness in synthetic biology: a route to continual innovation for biological design. Read Local generation and efficient evaluation of numerous drug combinations in a single sample. Read Vitarka Therapeutics, a company developing a non-viral drug delivery technology, raised £1.27
3 The scalable production of oestrogen led to its popularity and by the 1980-1990s, oestrogen (Premarin) was named the number one drug prescribed in the US. Hormone replacement requires treatment for the rest of a persons life thus, the greater the patient burden and number of side effects with a given drug, the lesser the compliance.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content